GlassScriptPhysician profile
Randall S Schwartz
NPI 1518259910
$2,043.13
in general payments reported to CMS, 2019-2025
20 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $369 · 2021: $26.40 · 2022: $15.65 · 2023: $98.52 · 2024: $87.02 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.23 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $330.61 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $303.08 | 2020-2025 | Breztri, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $239.04 | 2025 | Dupixent |
| Insmed, INC. | $192.68 | 2023-2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $140.25 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2020 | |
| Viatris Specialty LLC | $106.42 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.20 | 2019-2020 | |
| Genzyme Corporation | $89.80 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $84.38 | 2019-2020 | |
| Baxter Healthcare | $66.28 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $61.87 | 2025 | Glassia |
| Pulmonx Corporation | $50.00 | 2019 | |
| Mylan Specialty L.P. | $29.26 | 2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $29.23 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $22.50 | 2020 | |
| Philips North America LLC | $20.91 | 2019 | |
| Gilead Sciences, INC. | $18.34 | 2019 | |
| Boston Scientific Corporation | $18.23 | 2019 | |
| Nabriva Therapeutics, Plc | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.